Spinal muscular atrophy (SMA) is the leading genetic cause of death for infants. However you are impacted, we have information and resources to support your needs.
News Feed
Scholar Rock Presents TOPAZ Phase 2 Data Showing the Transformative Potential of Apitegromab in Patients with Type 2 and 3 SMA
Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, ...
New Genentech Data for Evrysdi Show Improved Motor Function in Pre-Symptomatic Babies After One Year and Confirm Safety Profile in Previously Treated People with SMA
Genentech, a member of the Roche Group, today announced new interim data from two studies of Evrysdi® (risdiplam)—JEWELFISH and RAINBOWFISH. Genentech leads the ...
Biogen Presents New Spinraza Data at the 2021 Virtual SMA Conference
Biogen Inc., today announced new research supporting the continued development of an investigational higher dose of SPINRAZA® (nusinersen) and additional data reinforcing ...
Community Spotlight
Community Spotlight: Dr. Arthur Burghes
On the 25th anniversary of the SMA Researcher Meeting, we would like you to learn more about Dr. Burghes and his ...
Community Spotlight: Doug McCullough
Doug McCullough was raised on a dairy farm in Pennsylvania and now resides in Central New Jersey. He is a self-described ...
Community Spotlight: Chan Family
Ten-year-old Brady Chan from North Carolina has big goals that stem from his passion for video games. He is part of an e-gaming team, where his favorite games ...
Cure SMA is committed to local support.
Find resources or a treatment site in your area.
Since 1984, we’ve invested $82 million in the research that has made today’s breakthroughs possible. We advance a comprehensive research program, attacking SMA from all sides.
The Cure SMA Care Center Network
Local, evidenced-based care centers, designed to develop an evidence-based standard of care to improve the lives of all those affected by SMA.
